Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections, complicated intra-abdominal infections who have limited or no alternative treatment options
The US Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP / VABP) in patients 18 years of age and older. Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options. Approval of this indication is based on limited clinical safety and efficacy data for Recarbrio.
“As a public health agency, the FDA addresses the threat of antimicrobial-resistant infections by facilitating the development of safe and effective new treatments,” said Sumathi Nambiar, Director, Division of Anti-Infectives, Office of Infectious Disease, FDA’s Center for Drug Evaluation and Research. “These efforts provide more options to fight serious bacterial infections and get new, safe and effective therapies to patients as soon as possible.”
HABP and VABP are a type of pneumonia that occurs in hospitalised patients and can cause symptoms such as fever, chills, cough, chest pain and increased oxygen requirements. Recarbrio is a combination of imipenem-cilastatin and relebactam. The drug is administered intravenously by a healthcare professional.
The safety and efficacy of Recarbrio for the treatment of HABP / VABP were evaluated in a randomised, controlled clinical trial of 535 hospitalised adults with HABP / VABP due gram-negative bacteria (a type of bacteria) in which 266 patients were treated with Recarbrio and 269 patients were treated with piperacillin-tazobactam, another antibacterial drug. Overall, 16 per cent of patients who received Recarbrio and 21 per cent of patients who received piperacillin-tazobactam died through Day 28 of the study.
The most common adverse reactions observed in patients treated with Recarbrio for HABP / VABP included increased aspartate / alanine aminotransferases (increased liver enzymes), anaemia, diarrhoea, hypokalaemia (low potassium) and hyponatremia (low sodium). Before initiating therapy with Recarbrio, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta lactams and other allergens. Recarbrio should not be used in patients who are prone to seizures and other central nervous system disorders. Clostridioides difficile-associated diarrhoea has been reported with use of nearly all antibacterial agents, including Recarbrio, and may range in severity from mild diarrhoea to fatal colitis.
This application was granted a Qualified Infectious Disease Programme (QIDP) designation. This designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act. Additionally, as part of QIDP designation, the FDA granted this application Fast Track and Priority Review designations.
The FDA is granting the approval to Merck & Co.